Adagio Medical Holdings, Inc Common Stock (ADGM)vsAstraZeneca PLC (AZN)
ADGM
Adagio Medical Holdings, Inc Common Stock
$0.62
-3.32%
HEALTHCARE · Cap: $16.55M
AZN
AstraZeneca PLC
$185.68
+1.45%
HEALTHCARE · Cap: $284.30B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 44115958% more annual revenue ($60.44B vs $137,000). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
ADGM
Avoid35
out of 100
Grade: F
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADGM.
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$185.68
$8.89 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 75.6% year-over-year
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ADGM
The strongest argument for ADGM centers on Revenue Growth, Price/Book. Revenue growth of 75.6% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ADGM
The primary concerns for ADGM are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 4.21 is elevated, increasing financial risk.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ADGM profiles as a hypergrowth stock while AZN is a mature play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.21 — expect wider price swings.
ADGM is growing revenue faster at 75.6% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 35/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adagio Medical Holdings, Inc Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Adagio Medical Holdings, Inc. is an innovative biotechnology firm dedicated to revolutionizing cardiac arrhythmia treatment through its state-of-the-art medical technologies. Utilizing its proprietary platform, the company is at the forefront of developing advanced targeted ablation techniques, addressing unmet needs in the electrophysiology sector. With a robust product pipeline and a seasoned leadership team, Adagio represents a compelling investment opportunity for institutional investors looking to capitalize on growth in the healthcare industry and contribute to improvements in cardiac patient outcomes.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?